IRD — Opus Genetics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1228627 ·
Last close
$4.05
Market Cap
$391.45M
52W High
$7.07
52W Low
$1.70
ADV30
1,288,842
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 755,000 | — | -16,480,000 | -8,098,000 | 92,968,000 | 88,812,000 | 105,954,000 |
| Mar 2026 | 2,157,000 | — | -14,364,000 | -65,535,000 | 66,787,000 | 59,959,000 | 112,623,000 |
| Dec 2025 | 3,865,000 | — | -11,453,000 | -16,523,000 | 50,243,000 | 45,091,000 | 34,895,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-48,546,000
Investing CF
$-189,000
Financing CF
$106,994,000
CapEx
—
Dividends Paid
—
Buybacks
$-149,000
EPS Diluted TTM
$-1.54
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-308,717,000
Inventory
—
Receivables
$1,633,000
ST Investments
$0
EBIT TTM
$-134,071,000
Pretax Income TTM
$-136,651,000
Interest Exp TTM
$2,580,000
Analysts
17
Yahoo Snapshot (yfinance, live)
Total Revenue
$7,914,000
EBITDA
$-61,482,000
Free Cash Flow
$-54,377,752
Enterprise Value
$331,591,264
Total Cash
$88,974,000
Total Debt
$35,881,000
Shares Out
96,654,336
Trailing EPS
$-1.48
Book Value
$0.40
ROE
-615.6%
ROA
-58.5%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 14,196,000 | -38,599,000 | -49,591,000 | 50,243,000 | 34,895,000 | 15,348,000 | -35,253,000 |
| Dec 2024 | 10,992,000 | -34,074,000 | -57,532,000 | 36,862,000 | 30,138,000 | 6,724,000 | -25,576,000 |
| Dec 2023 | 19,049,000 | -10,563,000 | -9,986,000 | 53,948,000 | 4,042,000 | 49,906,000 | -1,112,000 |
| Dec 2022 | 39,850,000 | 18,226,000 | 17,888,000 | 48,992,000 | 2,753,000 | 46,239,000 | 14,314,000 |
TTM Snapshot
Revenues TTM
$9,856,000
NetIncome TTM
$-107,610,000
OpCashFlow TTM
—
Assets (Latest)
$92,968,000
Forward EPS
$-0.76
Max Pain — expiry 2027-02-19
max pain strike: $5.00 · spot: $3.92 · call oi: 4,577 · put oi: 206
Expected Move to 2027-02-19:
±$2.90
(73.98%) —
implied range
$1.02 –
$6.82
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RZLT | Rezolute, Inc. | $388.37M | $4.01 | — |
| ELTP | ELITE PHARMACEUTICALS INC /NV/ | $397.36M | $0.37 | — |
| PTCHF | PureTech Health plc | $405.77M | $1.65 | — |
| AVTX | Avalo Therapeutics, Inc. | $412.28M | $7.13 | — |
| CRMD | CorMedix Inc. | $371.44M | $4.67 | — |
News headlines (Yahoo Finance, 1h cache)
Opus Genetics, Inc. (IRD) Reports Q3 Loss, Lags Revenue Estimates
2026-11-10 12:25 · Yahoo
Opus Genetics Announces Financial Results for Third Quarter 2026 and Provides Corporate Update
2026-11-10 12:00 · Yahoo
Opus Genetics Completes Dosing in Cohort 2 of Phase 1/2 Clinical Trial of OPGx-BEST1 Gene Therapy for Inherited Retinal Diseases
2026-11-05 12:00 · Yahoo
Opus Genetics to Present at the Guggenheim Annual Healthcare Innovation Conference
2026-11-03 12:00 · Yahoo
Opus Genetics Appoints Dr. Andrew Murphy as Chief Scientific Officer and Jamie Lynne Hart as Executive Director, Executive Operations
2026-10-29 11:00 · Yahoo
Opus Genetics Eyes 2029 Runway as Presbyopia Drop Wins FDA Approval
2026-10-25 12:02 · Yahoo
Opus Genetics Announces FDA Clearance of IND Application for OPGx-RDH12 Gene Therapy for Inherited Childhood Blindness
2026-10-21 11:00 · Yahoo
Opus Genetics Secures FDA Approval For Eye Drops – Set To Receive Milestone Payment
2026-10-16 17:58 · Yahoo
Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
2026-10-16 16:00 · Yahoo
Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026
2026-10-15 20:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.